Amuvatinib (Standard)

Overview

Amuvatinib (Standard) is the analytical standard of Amuvatinib. This product is intended for research and analytical applications. Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit , PDGFRα , Flt3 , c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51 , thereby disrupting DNA damage repair. Antineoplastic activity.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > FLT3 | Products > Signaling Pathways > c-Met/HGFR | Products > Signaling Pathways > RET | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > c-Kit | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > RAD51

Product Information

• Catalog No.: HY-10206R
• CAS No.: 850879-09-3
• Molecular Formula: C23H21N5O3S
• Molecular Weight: 447.51
• Purity: 98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source